Objective: To evaluate the efficacy of treatment at 1 year after completing the 2-year specific sublingual immunotherapy in patients with allergic rhinitis (AR). Methods: A retrospective analysis of 124 patients with AR who were allergic to dust mite and treated in the First Affiliated Hospital of Wenzhou Medical University since 2012 was performed. All patients achieved sublingual immunotherapy (SLIT) for 2 years and had a regular follow-up over 1 year. Efficacy evaluation index such as VAS score, total nasal symptom score and total medication score were compared between the time of SLIT for 2 years, and 1 year after termination of SLIT. Paired t test was used for the comparison of scores. Results: Compared with those before treatment, the VAS score, total nasal symptom score and total medication score at the time of SLIT for 2 years were significantly decreased in all patients with AR [(9.40±5.96) vs (24.78±6.36), (4.53±2.06) vs (9.51±2.02), (0.42±0.87) vs (3.02±0.41), t value was 17.627, 24.600, 5.331, respectively, all P<0.01]. Compared with 2 years SLIT treatment, VAS score and total nasal symptom score were significantly increased than 1 year after termination of immunotherapy [(12.52±6.92) vs (9.40±5.96), (5.30±2.36) vs (4.53±2.06), t=5.199, 3.744, respectively, all P<0.01], but the total medication score showed no significant difference [(0.34±0.84) vs (0.42±0.87), t=-1.043, P>0.05]. Conclusions: The symptoms after 2 years SLIT in patients with AR have been well controlled. One year after the termination of SLIT, there is a certain rebound in symptoms, 2 years SLIT may not be the ideal treatment cycle for AR.
目的： 评估变应性鼻炎(allergic rhinitis，AR)患者经舌下免疫治疗(sublingual immunotherapy，SLIT)满2年终止1年时的疗效。 方法： 回顾性分析2012年以来就诊于温州医科大学附属第一医院耳鼻咽喉头颈外科的124例对粉尘螨过敏的AR患者，这些患者完成了2年的舌下免疫治疗且终止免疫治疗1年以上。比较治疗满2年时、终止免疫治疗后1年时的疗效评估指标[视觉模拟量表(visual analogue scale，VAS)评分、鼻炎症状评分、用药评分]的变化。采用配对t检验的统计学方法，以P<0.05为差异有统计学意义。 结果： 与治疗前相比，SLIT治疗2年时，所有AR患者VAS评分、鼻炎症状评分、药物评分均显著降低[(9.40±5.96)分比(24.78±6.36)分，(4.53±2.06)分比(9.51±2.02)分，(0.42±0.87)分比(3.02±0.41)分，t值分别为17.627、24.600、5.331，P值均<0.01]；终止SLIT 1年后与治疗2年时相比，VAS评分、鼻炎症状评分均增高[(12.52±6.92)分比(9.40±5.96)分，(5.30±2.36)分比(4.53±2.06)分，t值分别为5.199、3.744，P值均<0.01]，药物评分未见明显差异[(0.34±0.84)分比(0.42±0.87)分，t＝－1.043，P>0.05)。 结论： AR患者经过2年的SLIT后症状得到了较好的控制；终止治疗1年后AR症状存在一定的反复趋势，即2年可能不是SLIT的理想治疗周期。.
Keywords: Administration, sublingual; Dermatophagoides farinae; Immunity; Rhinitis, allergic; Treatment outcome.